173 related articles for article (PubMed ID: 21481181)
41. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
42. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
43. Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Lu T; Markotan T; Ballentine SK; Giardino EC; Spurlino J; Crysler CS; Brown K; Maryanoff BE; Tomczuk BE; Damiano BP; Shukla U; End D; Andrade-Gordon P; Bone RF; Player MR
J Med Chem; 2010 Feb; 53(4):1843-56. PubMed ID: 20102150
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
[TBL] [Abstract][Full Text] [Related]
45. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
Chen D; Wang S; Diao X; Zhu Q; Shen H; Han X; Wang Y; Gong G; Xu Y
Bioorg Med Chem; 2015 Dec; 23(23):7405-16. PubMed ID: 26537784
[TBL] [Abstract][Full Text] [Related]
47. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
[TBL] [Abstract][Full Text] [Related]
48. γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Sheffield WP; Lambourne MD; Eltringham-Smith LJ; Bhakta V; Arnold DM; Crowther MA
J Thromb Haemost; 2014 Jul; 12(7):1110-5. PubMed ID: 24815541
[TBL] [Abstract][Full Text] [Related]
49. Dabigatran etexilate in venous thromboembolism.
Ferrer E
Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
[TBL] [Abstract][Full Text] [Related]
50. [Monitoring of Oral Thrombin Inhibitor].
Matsuno K; Usami T; Hatuse M; Shimizu C
Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
52. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
53. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
54. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.
Halbmayer WM; Weigel G; Quehenberger P; Tomasits J; Haushofer AC; Aspoeck G; Loacker L; Schnapka-Koepf M; Goebel G; Griesmacher A
Clin Chem Lab Med; 2012; 50(9):1601-5. PubMed ID: 23100377
[TBL] [Abstract][Full Text] [Related]
55. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
Liesenfeld KH; Lehr T; Dansirikul C; Reilly PA; Connolly SJ; Ezekowitz MD; Yusuf S; Wallentin L; Haertter S; Staab A
J Thromb Haemost; 2011 Nov; 9(11):2168-75. PubMed ID: 21972820
[TBL] [Abstract][Full Text] [Related]
56. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
Dzeshka MS; Lip GY
Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
[TBL] [Abstract][Full Text] [Related]
57. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Ieko M
Curr Opin Investig Drugs; 2007 Sep; 8(9):758-68. PubMed ID: 17729188
[TBL] [Abstract][Full Text] [Related]
58. The pharmacology and therapeutic use of dabigatran etexilate.
Sarah S
J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
[TBL] [Abstract][Full Text] [Related]
59. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304
[TBL] [Abstract][Full Text] [Related]
60. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity.
Berry CN; Lassalle G; Lunven C; Altenburger JM; Guilbert F; Lalé A; Hérault JP; Lecoffre C; Pfersdorff C; Herbert JM; O'Connor SE
J Pharmacol Exp Ther; 2002 Dec; 303(3):1189-98. PubMed ID: 12438543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
